ReviewCurrent hematologic malignancy reports2020
Thrombocytosis and Thrombosis: Is There Really a Correlation?
Review in Current hematologic malignancy reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Clinical and Molecular Insights of Arterial and Venous Thrombosis in Myeloproliferative Diseases-Case-Based Narrative Review.Biomedicines · 2025Review
- Article
- Successful treatment of a chronic myeloid leukemia patient with extreme thrombocytosis by a combination of imatinib and interferon‑α: A case report.Experimental and therapeutic medicine · 2025Article
- Etiology of patients with extreme thrombocytosis and its association with coagulation function: 10-year experience in a tertiary hospital.Frontiers in medicine · 2025Article
- Risk of bleeding in patients with essential thrombocythemia and extreme thrombocytosis.Blood advances · 2024Article
- Baseline platelet count and long-term clinical outcomes in patients with acute venous thromboembolism: a prospective cohort study.Annals of hematology · 2024Article
- DARS expression in BCR/ABL1-negative myeloproliferative neoplasms and its association with the immune microenvironment.Scientific reports · 2024Article
- Prediction of acute coronary syndrome in patients with myeloproliferative neoplasms.Frontiers in cardiovascular medicine · 2024Article
- Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group.Clinical and experimental medicine · 2023Review
- Myeloproliferative Neoplasms and Aspirin: Does Increased Platelet Turnover Matter?Turkish journal of haematology : official journal of Turkish Society of Haematology · 2023Article
- Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patients.American journal of hematology · 2022Article
- Clinical characteristics, prognostic factors, and outcomes of patients with essential thrombocythemia in Japan: the JSH-MPN-R18 study.International journal of hematology · 2022Observational
- Platelets Contribution to Thrombin Generation in Philadelphia-Negative Myeloproliferative Neoplasms: The "Circulating Wound" Model.International journal of molecular sciences · 2021Review
- Management Issues and Controversies in Low-Risk Patients with Essential Thrombocythemia and Polycythemia Vera.Current hematologic malignancy reports · 2021Review
- Therapeutic Plateletpheresis in Patients With Thrombocytosis: Gender, Hemoglobin Before Apheresis Significantly Affect Collection Efficiency.Frontiers in medicine · 2021Article
- Evaluation of Therapeutic Strategies to Reduce the Number of Thrombotic Events in Patients With Polycythemia Vera and Essential Thrombocythemia.Frontiers in oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThrombocytosis is common to all myeloproliferative neoplasms (MPN), including essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis. Despite the traditionally held belief amongst many clinicians that thrombocytosis correlates with thrombosis risk, there is little evidence in the literature to support that claim. Herein we critically analyze the literature to better understand the relationship between thrombocytosis and risk of thrombosis in MPN. RECENT
findingsBoth retrospective and prospective studies argue against associations between thrombocytosis and risk of thrombosis in patients with ET and PV. Rather, most studies suggest that the presence of extreme thrombocytosis is instead associated with an increased risk of hemorrhagic events, a paradoxical phenomenon with important clinical implications. Thrombosis risk has a multifactorial set of etiologies in MPNs. While qualitative abnormalities of the platelets may contribute, associations between platelet quantity and thrombosis risk are weak in MPN patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.